Studies of the biogenic amine transporters. 12. Identification of novel partial inhibitors of amphetamine-induced dopamine release

Joseph J. Pariser, John S. Partilla, Christina M. Dersch, Subramaniam Ananthan, Richard B. Rothman

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Previous studies identified partial inhibitors and allosteric modulators of 5-hydroxytryptamine ([5-amino-3-(3,4-dichlorophenyl)-1,2-dihydropyrido[3,4-b] pyrazin-7-yl]carbamic acid ethyl ester [SoRI-6238], 4-(2-[bis(4-fluorophenyl) methoxy]ethyl)-1-(2-trifluoromethyl-benzyl)-piperidine [TB-1-099]) and dopamine transporters N-(diphenylmethyl)-2-phenyl-4-quinazolinamine, [SoRI-9804]). We report here the identification of three novel allosteric modulators of the dopamine transporter [N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine [SoRI-20040], N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine [SoRI-20041], and [4-amino-6-[(diphenylmethyl)amino]-5-nitro-2-pyridinyl]carbamic acid ethyl ester [SoRI-2827]]. Membranes were prepared from human embryonic kidney cells expressing the cloned human dopamine transporter (hDAT). [125I] 3β-(4′-Iodophenyl)tropan-2β-carboxylic acid methyl ester ([ 125I]RTI-55) binding and other assays followed published procedures. SoRI-20040, SoRI-20041, and SoRI-2827 partially inhibited [125I]RTI- 55 binding, with EC50 values ranging from ∼1.4 to 3 μM and Emax values decreasing as the [125I]RTI-55 concentrations increased. All three compounds decreased the [125I]RTI-55 B max value and increased the apparent Kd value in a manner well described by a sigmoid dose-response curve. In dissociation rate experiments, SoRI-20040 (10 μM) and SoRI-20041 (10 μM), but not SoRI-2827 (10 μM), slowed the dissociation of [125I]RTI-55 from hDAT by ∼30%. Using rat brain synaptosomes, all three agents partially inhibited [3H]dopamine uptake, with EC50 values ranging from 1.8 to 3.1 μM and decreased the Vmax value in a dose-dependent manner. SoRI-9804 and SoRI-20040 partially inhibited amphetamine-induced dopamine transporter-mediated release of [3H]1-methyl-4-phenylpyridinium ion from rat caudate synaptosomes in a dose-dependent manner. Viewed collectively, we report several compounds that allosterically modulate hDAT binding and function, and we identify novel partial inhibitors of amphetamine-induced dopamine release.

Original languageEnglish (US)
Pages (from-to)286-295
Number of pages10
JournalJournal of Pharmacology and Experimental Therapeutics
Volume326
Issue number1
DOIs
StatePublished - Jul 1 2008

Fingerprint

Dopamine Plasma Membrane Transport Proteins
Biogenic Amines
Amphetamine
Dopamine
Synaptosomes
Urethane
1-Methyl-4-phenylpyridinium
Sigmoid Colon
Carboxylic Acids
Serotonin
Esters
RTI 55
Kidney
Membranes
Brain

Cite this

Studies of the biogenic amine transporters. 12. Identification of novel partial inhibitors of amphetamine-induced dopamine release. / Pariser, Joseph J.; Partilla, John S.; Dersch, Christina M.; Ananthan, Subramaniam; Rothman, Richard B.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 326, No. 1, 01.07.2008, p. 286-295.

Research output: Contribution to journalArticle

Pariser, Joseph J. ; Partilla, John S. ; Dersch, Christina M. ; Ananthan, Subramaniam ; Rothman, Richard B. / Studies of the biogenic amine transporters. 12. Identification of novel partial inhibitors of amphetamine-induced dopamine release. In: Journal of Pharmacology and Experimental Therapeutics. 2008 ; Vol. 326, No. 1. pp. 286-295.
@article{6de472268139402d870e1c28a87a342a,
title = "Studies of the biogenic amine transporters. 12. Identification of novel partial inhibitors of amphetamine-induced dopamine release",
abstract = "Previous studies identified partial inhibitors and allosteric modulators of 5-hydroxytryptamine ([5-amino-3-(3,4-dichlorophenyl)-1,2-dihydropyrido[3,4-b] pyrazin-7-yl]carbamic acid ethyl ester [SoRI-6238], 4-(2-[bis(4-fluorophenyl) methoxy]ethyl)-1-(2-trifluoromethyl-benzyl)-piperidine [TB-1-099]) and dopamine transporters N-(diphenylmethyl)-2-phenyl-4-quinazolinamine, [SoRI-9804]). We report here the identification of three novel allosteric modulators of the dopamine transporter [N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine [SoRI-20040], N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine [SoRI-20041], and [4-amino-6-[(diphenylmethyl)amino]-5-nitro-2-pyridinyl]carbamic acid ethyl ester [SoRI-2827]]. Membranes were prepared from human embryonic kidney cells expressing the cloned human dopamine transporter (hDAT). [125I] 3β-(4′-Iodophenyl)tropan-2β-carboxylic acid methyl ester ([ 125I]RTI-55) binding and other assays followed published procedures. SoRI-20040, SoRI-20041, and SoRI-2827 partially inhibited [125I]RTI- 55 binding, with EC50 values ranging from ∼1.4 to 3 μM and Emax values decreasing as the [125I]RTI-55 concentrations increased. All three compounds decreased the [125I]RTI-55 B max value and increased the apparent Kd value in a manner well described by a sigmoid dose-response curve. In dissociation rate experiments, SoRI-20040 (10 μM) and SoRI-20041 (10 μM), but not SoRI-2827 (10 μM), slowed the dissociation of [125I]RTI-55 from hDAT by ∼30{\%}. Using rat brain synaptosomes, all three agents partially inhibited [3H]dopamine uptake, with EC50 values ranging from 1.8 to 3.1 μM and decreased the Vmax value in a dose-dependent manner. SoRI-9804 and SoRI-20040 partially inhibited amphetamine-induced dopamine transporter-mediated release of [3H]1-methyl-4-phenylpyridinium ion from rat caudate synaptosomes in a dose-dependent manner. Viewed collectively, we report several compounds that allosterically modulate hDAT binding and function, and we identify novel partial inhibitors of amphetamine-induced dopamine release.",
author = "Pariser, {Joseph J.} and Partilla, {John S.} and Dersch, {Christina M.} and Subramaniam Ananthan and Rothman, {Richard B.}",
year = "2008",
month = "7",
day = "1",
doi = "10.1124/jpet.108.139675",
language = "English (US)",
volume = "326",
pages = "286--295",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Studies of the biogenic amine transporters. 12. Identification of novel partial inhibitors of amphetamine-induced dopamine release

AU - Pariser, Joseph J.

AU - Partilla, John S.

AU - Dersch, Christina M.

AU - Ananthan, Subramaniam

AU - Rothman, Richard B.

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Previous studies identified partial inhibitors and allosteric modulators of 5-hydroxytryptamine ([5-amino-3-(3,4-dichlorophenyl)-1,2-dihydropyrido[3,4-b] pyrazin-7-yl]carbamic acid ethyl ester [SoRI-6238], 4-(2-[bis(4-fluorophenyl) methoxy]ethyl)-1-(2-trifluoromethyl-benzyl)-piperidine [TB-1-099]) and dopamine transporters N-(diphenylmethyl)-2-phenyl-4-quinazolinamine, [SoRI-9804]). We report here the identification of three novel allosteric modulators of the dopamine transporter [N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine [SoRI-20040], N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine [SoRI-20041], and [4-amino-6-[(diphenylmethyl)amino]-5-nitro-2-pyridinyl]carbamic acid ethyl ester [SoRI-2827]]. Membranes were prepared from human embryonic kidney cells expressing the cloned human dopamine transporter (hDAT). [125I] 3β-(4′-Iodophenyl)tropan-2β-carboxylic acid methyl ester ([ 125I]RTI-55) binding and other assays followed published procedures. SoRI-20040, SoRI-20041, and SoRI-2827 partially inhibited [125I]RTI- 55 binding, with EC50 values ranging from ∼1.4 to 3 μM and Emax values decreasing as the [125I]RTI-55 concentrations increased. All three compounds decreased the [125I]RTI-55 B max value and increased the apparent Kd value in a manner well described by a sigmoid dose-response curve. In dissociation rate experiments, SoRI-20040 (10 μM) and SoRI-20041 (10 μM), but not SoRI-2827 (10 μM), slowed the dissociation of [125I]RTI-55 from hDAT by ∼30%. Using rat brain synaptosomes, all three agents partially inhibited [3H]dopamine uptake, with EC50 values ranging from 1.8 to 3.1 μM and decreased the Vmax value in a dose-dependent manner. SoRI-9804 and SoRI-20040 partially inhibited amphetamine-induced dopamine transporter-mediated release of [3H]1-methyl-4-phenylpyridinium ion from rat caudate synaptosomes in a dose-dependent manner. Viewed collectively, we report several compounds that allosterically modulate hDAT binding and function, and we identify novel partial inhibitors of amphetamine-induced dopamine release.

AB - Previous studies identified partial inhibitors and allosteric modulators of 5-hydroxytryptamine ([5-amino-3-(3,4-dichlorophenyl)-1,2-dihydropyrido[3,4-b] pyrazin-7-yl]carbamic acid ethyl ester [SoRI-6238], 4-(2-[bis(4-fluorophenyl) methoxy]ethyl)-1-(2-trifluoromethyl-benzyl)-piperidine [TB-1-099]) and dopamine transporters N-(diphenylmethyl)-2-phenyl-4-quinazolinamine, [SoRI-9804]). We report here the identification of three novel allosteric modulators of the dopamine transporter [N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine [SoRI-20040], N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine [SoRI-20041], and [4-amino-6-[(diphenylmethyl)amino]-5-nitro-2-pyridinyl]carbamic acid ethyl ester [SoRI-2827]]. Membranes were prepared from human embryonic kidney cells expressing the cloned human dopamine transporter (hDAT). [125I] 3β-(4′-Iodophenyl)tropan-2β-carboxylic acid methyl ester ([ 125I]RTI-55) binding and other assays followed published procedures. SoRI-20040, SoRI-20041, and SoRI-2827 partially inhibited [125I]RTI- 55 binding, with EC50 values ranging from ∼1.4 to 3 μM and Emax values decreasing as the [125I]RTI-55 concentrations increased. All three compounds decreased the [125I]RTI-55 B max value and increased the apparent Kd value in a manner well described by a sigmoid dose-response curve. In dissociation rate experiments, SoRI-20040 (10 μM) and SoRI-20041 (10 μM), but not SoRI-2827 (10 μM), slowed the dissociation of [125I]RTI-55 from hDAT by ∼30%. Using rat brain synaptosomes, all three agents partially inhibited [3H]dopamine uptake, with EC50 values ranging from 1.8 to 3.1 μM and decreased the Vmax value in a dose-dependent manner. SoRI-9804 and SoRI-20040 partially inhibited amphetamine-induced dopamine transporter-mediated release of [3H]1-methyl-4-phenylpyridinium ion from rat caudate synaptosomes in a dose-dependent manner. Viewed collectively, we report several compounds that allosterically modulate hDAT binding and function, and we identify novel partial inhibitors of amphetamine-induced dopamine release.

UR - http://www.scopus.com/inward/record.url?scp=45749089693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45749089693&partnerID=8YFLogxK

U2 - 10.1124/jpet.108.139675

DO - 10.1124/jpet.108.139675

M3 - Article

C2 - 18441249

AN - SCOPUS:45749089693

VL - 326

SP - 286

EP - 295

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -